ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 011

Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings

Martina Capponi 1, Denise Pires Marafon 2, Flaminia Rivosecchi 1, Manuela Pardeo2, Fabrizio De Benedetti 2 and Antonella Insalaco 2, 1IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: Clinical Response, CRMO, Imaging

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Title: Poster Breakout 1 – Advances in Diagnosis & Classification

Session Type: Poster Breakout Session

Session Time: 5:10PM-5:40PM

Background/Purpose: Due to the lack of widely accepted diagnostic criteria or disease biomarkers, chronic non-bacterial osteomyelitis (CNO) remains a diagnosis of exclusion. Whole-body MRI (WB-MRI) has become one of the mainstays in supporting the diagnosis of CNO. The aim of our study was to create a scoring system (MRI-score), based on recently developed scoring tool for MRI CROMRIS (Chronic nonbacterial Osteomyelitis MRI Scoring), which allows a standardized reporting of WB-MRI in order to obtain a tool useful for the staging of the disease and for the follow up.1 We evaluate correlation of our MRI-score with clinical activity parameters and with the response to treatment.

Methods: We analyzed 76 patients that met the criteria proposed by Jansson et al. for the diagnosis of CNO2. We collected at baseline (T0), before starting any treatment, clinical and radiological findings. Clinical disease activity was evaluated using a Physician’s Global Assessment (PGA). WB-MRI images were assessed using the CROMRIS as published by Zhao Y et al. According to CROMRIS, parameters included in our MRI-score were: 1) presence of bone marrow hyperintensity on STIR images, 2) signal extension, 3) presence of soft tissue/periosteal hyperintensity, 4) presence of bony expansion, 5) presence of vertebral collapse. These parameters were evaluated for each bone units grading a score from 0 to 7. In 46 of the 76 patients MRI-score, the main clinical parameters (PGA, pain VAS, ESR and CRP) and the response to therapy was evaluated also at 6 and 12 months (T6 and T12) following baseline.

Results: A significant association between the MRI-score and some disease clinical parameters (PGA, presence of functional impairment, abnormal ESR and CRP level) was found in the 76 patients at baseline (figure 1). Among 46 patients followed for 12 months, the MRI-score, PGA, pain VAS, ESR and CRP showed a decreasing trend after 6 months from baseline that remained substantially stable at 12 months. Moreover a significant correlation between the MRI-score and the PGA was observed at baseline (p=0.0044; rho=0.41), but not at T6 and T12 (figure 2). Furthermore, patients who received bisphosphonates as first-line therapy showed a substantial decrease of the MRI-score at T6 compared to T0 (figure 3). In these patients the MRI-score was significantly higher compared to patients who received other treatment at baseline (p=0.0078).

Conclusion: In conclusion our MRI-score offers a standardized reporting system which, together with the clinical evaluation, may contribute to the diagnosis of CNO patients. Moreover, the proposed MRI-score may represent a valid tool to stratify patients with CNO based on the severity of the disease and consequently to guide the most appropriate therapeutic choice. Finally, MRI-score, allowing an objective evaluation of the effectiveness of different treatments, could possibly be included into recommendation of management of patients with CNO.

1 Zhao Y et al. J Rheumathol. 2019

2 Jansson AF et al. Arthritis Rheum. 2009

Figure 1: Association between the MRI_score and disease clinical parameters. At baseline there is a significant association between the MRI_score and the PGA, the presence of functional impairment, the ESR>15 mm/hr and the CRP>=0.15 mg/dl.

Figure 2: The correlation between the MRI_score and the PGA during follow_up. A significant correlation between the MRI_score and the PGA is observed at baseline, but not at T6 and T12.

Figure 3: The MRI_score trend in response to bisphosphonates therapy. Patients who received bisphosphonates as first_line therapy showed a substantial decrease of the MRI_score at T6 compared to T0.


Disclosure: M. Capponi, None; D. Pires Marafon, None; F. Rivosecchi, None; M. Pardeo, None; F. De Benedetti, Novartis, 1, 2, Novimmune, 1, Sobi, 1, 2, Roche, 1, 2, Pfizer, 1, Sanofi, 1, AbbVie, 1, Novimmune/Sobi, 1; A. Insalaco, None.

To cite this abstract in AMA style:

Capponi M, Pires Marafon D, Rivosecchi F, Pardeo M, De Benedetti F, Insalaco A. Chronic Non-bacterial Osteomyelitis (CNO): Correlation Between Clinical and Radiological Findings [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/chronic-non-bacterial-osteomyelitis-cno-correlation-between-clinical-and-radiological-findings/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-non-bacterial-osteomyelitis-cno-correlation-between-clinical-and-radiological-findings/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology